OTCPK:VPAH.F

Stock Analysis Report

Volpara Health Technologies

Executive Summary

Volpara Health Technologies Limited provides breast imaging analytics and analysis products for the early detection of breast cancer in the medical device software industry.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has Volpara Health Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

10.1%

VPAH.F

-2.1%

US Healthcare Services

0.07%

US Market


1 Year Return

n/a

VPAH.F

18.1%

US Healthcare Services

8.9%

US Market

Return vs Industry: Insufficient data to determine how VPAH.F performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how VPAH.F performed against the US Market.


Shareholder returns

VPAH.FIndustryMarket
7 Day10.1%-2.1%0.07%
30 Day11.6%-5.4%-0.3%
90 Dayn/a-10.1%-1.6%
1 Yearn/a18.3%18.1%11.3%8.9%
3 Yearn/a65.0%64.5%46.3%36.8%
5 Yearn/a60.9%59.6%62.1%44.3%

Price Volatility Vs. Market

How volatile is Volpara Health Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Volpara Health Technologies undervalued compared to its fair value and its price relative to the market?

22.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: VPAH.F ($1.2) is trading above our estimate of fair value ($0.18)

Significantly Below Fair Value: VPAH.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VPAH.F is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: VPAH.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VPAH.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VPAH.F is overvalued based on its PB Ratio (22.4x) compared to the US Healthcare Services industry average (3.5x).


Next Steps

Future Growth

How is Volpara Health Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

59.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VPAH.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: VPAH.F is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: VPAH.F's loss is forecast to worsen by 0% next year.

Revenue vs Market: VPAH.F's revenue (53.5% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: VPAH.F's revenue (53.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VPAH.F's Return on Equity is forecast to be low in 3 years time (11.5%).


Next Steps

Past Performance

How has Volpara Health Technologies performed over the past 5 years?

6.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VPAH.F is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.

Accelerating Growth: Unable to compare VPAH.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VPAH.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-5.7%).


Return on Equity

High ROE: VPAH.F has a negative Return on Equity (-82.79%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: VPAH.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VPAH.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Volpara Health Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: VPAH.F's short term assets (NZ$17.1M) exceeds its short term liabilities (NZ$4.6M)

Long Term Liabilities: VPAH.F's short term assets (17.1M) exceeds its long term liabilities (146.0K)


Debt to Equity History and Analysis

Debt Level: VPAH.F is debt free.

Reducing Debt: VPAH.F currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: VPAH.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if VPAH.F's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VPAH.F has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VPAH.F has sufficient cash runway for 1.107887 years if free cash flow continues to reduce at historical rates of -28% each year.


Next Steps

Dividend

What is Volpara Health Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VPAH.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VPAH.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VPAH.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VPAH.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VPAH.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Volpara Health Technologies's salary, the management and board of directors tenure and is there insider trading?

0.3yrs

Average management tenure


CEO

Ralph Highnam 0

0yrs

Tenure

NZ$422,394

Compensation

Dr. Ralph Highnam, Ph.D. serves as the Chief Executive Officer and Chief Scientist at Volpara Health Technologies Limited. Dr. Highnam has been Executive Director at Volpara Health Technologies Limited sin ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Ralph's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Ralph's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

0.3yrs

Average Tenure

Experienced Management: VPAH.F's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Age and Tenure

4.8yrs

Average Tenure

73yo

Average Age

Experienced Board: VPAH.F's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: VPAH.F insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellNZ$2,182,81011 Sep 19
Roger Allen
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares2,000,000
Max PriceNZ$1.09
SellNZ$2,182,81011 Sep 19
Ralph Highnam
EntityIndividual
Role
Chief Executive Officer
CEO, Chief Scientist
Shares2,000,000
Max PriceNZ$1.09
SellNZ$877,73411 Sep 19
John Brady
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director & Member of Scientific Advisory Board
Shares800,000
Max PriceNZ$1.10
SellNZ$327,42211 Sep 19
John Diddams
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares300,000
Max PriceNZ$1.09
BuyNZ$16,69217 Jun 19
John Diddams
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares16,100
Max PriceNZ$1.04
BuyNZ$1,747,26314 Jun 19
Harbour Asset Management Limited
EntityCompany
Shares1,907,654
Max PriceNZ$1.17
SellNZ$171,26414 Jun 19
Harbour Asset Management Limited
EntityCompany
Shares146,324
Max PriceNZ$1.19
BuyNZ$277,63828 Feb 19
Harbour Asset Management Limited
EntityCompany
Shares351,634
Max PriceNZ$0.92
BuyNZ$352,91908 Nov 18
Harbour Asset Management Limited
EntityCompany
Shares406,951
Max PriceNZ$0.94
SellNZ$844,79408 Nov 18
Harbour Asset Management Limited
EntityCompany
Shares842,366
Max PriceNZ$1.08

Ownership Breakdown


Management Team

  • Mark Koeniguer

    Chief Commercial Officer & President of USA

    • Tenure: 0yrs
    • Compensation: NZ$545.45k
  • Ralph Highnam

    CEO, Chief Scientist

    • Tenure: 0yrs
    • Compensation: NZ$422.39k
  • Nico Karssemeijer

    Co-Founder & Member of Scientific Board

    • Tenure: 0yrs
  • Julian Marshall

    Chief Product Officer

    • Tenure: 0yrs
    • Compensation: NZ$510.51k
  • David Murray

    Chief Technology Officer

    • Tenure: 0yrs
    • Compensation: NZ$259.00k
  • Craig Hadfield

    CFO & Company Secretary

    • Tenure: 2.6yrs
    • Compensation: NZ$219.51k
  • Monica Saini

    Executive Director & Chief Medical Officer

    • Tenure: 1.2yrs
    • Compensation: NZ$319.82k
  • Kathryn Greene

    Chief People Officer

    • Tenure: 0.3yrs
  • Simon Francis

    Chief Operating Officer

    • Tenure: 0.2yrs

Board Members

  • Roger Allen (73yo)

    Non-Executive Director

    • Tenure: 9.3yrs
    • Compensation: NZ$102.48k
  • Mike Brady (74yo)

    Non-Executive Director & Member of Scientific Advisory Board

    • Tenure: 10.8yrs
    • Compensation: NZ$64.98k
  • Martin Yaffe

    Member of Scientific Board

    • Tenure: 0yrs
  • John Diddams (69yo)

    Independent Non-Executive Director

    • Tenure: 4.8yrs
    • Compensation: NZ$80.00k
  • Ralph Highnam

    CEO, Chief Scientist

    • Tenure: 0yrs
    • Compensation: NZ$422.39k
  • Nico Karssemeijer

    Co-Founder & Member of Scientific Board

    • Tenure: 0yrs
  • Jennifer Harvey

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Ard den Heeten

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Paul Robert Reid

    Independent Chairman of the Board

    • Tenure: 0.6yrs
    • Compensation: NZ$128.58k
  • Monica Saini

    Executive Director & Chief Medical Officer

    • Tenure: 1.2yrs
    • Compensation: NZ$319.82k

Company Information

Volpara Health Technologies Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Volpara Health Technologies Limited
  • Ticker: VPAH.F
  • Exchange: OTCPK
  • Founded: 2009
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$360.893m
  • Listing Market Cap: AU$247.764m
  • Shares outstanding: 218.06m
  • Website: https://volparasolutions.com

Number of Employees


Location

  • Volpara Health Technologies Limited
  • 44 Victoria Street
  • Level 7
  • Wellington
  • 6011
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VHTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDApr 2016
VHTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDApr 2016
VPAH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 2016

Biography

Volpara Health Technologies Limited provides breast imaging analytics and analysis products for the early detection of breast cancer in the medical device software industry. The company offers VolparaEnter ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:49
End of Day Share Price2019/10/22 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.